| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 90 | 2024 | 2073 | 4.520 |
Why?
|
| Aging | 72 | 2023 | 1503 | 3.640 |
Why?
|
| Cognitive Dysfunction | 45 | 2023 | 1043 | 3.230 |
Why?
|
| Brain | 61 | 2024 | 1604 | 3.120 |
Why?
|
| Cognition Disorders | 51 | 2023 | 961 | 3.060 |
Why?
|
| Parkinson Disease | 47 | 2023 | 664 | 2.630 |
Why?
|
| Aged, 80 and over | 159 | 2024 | 4633 | 2.560 |
Why?
|
| Aged | 202 | 2024 | 8658 | 2.420 |
Why?
|
| Male | 251 | 2024 | 14176 | 2.360 |
Why?
|
| Female | 253 | 2024 | 14543 | 2.300 |
Why?
|
| Cognition | 45 | 2024 | 1307 | 2.110 |
Why?
|
| Humans | 292 | 2024 | 25900 | 2.040 |
Why?
|
| Hallucinations | 13 | 2011 | 42 | 1.610 |
Why?
|
| Longitudinal Studies | 54 | 2023 | 1324 | 1.430 |
Why?
|
| Neuropsychological Tests | 50 | 2023 | 1164 | 1.340 |
Why?
|
| Dementia | 19 | 2022 | 537 | 1.310 |
Why?
|
| Cohort Studies | 57 | 2024 | 1815 | 1.200 |
Why?
|
| Parkinsonian Disorders | 10 | 2023 | 215 | 1.110 |
Why?
|
| Tourette Syndrome | 7 | 2009 | 11 | 1.110 |
Why?
|
| Independent Living | 16 | 2023 | 300 | 1.080 |
Why?
|
| Magnetic Resonance Imaging | 27 | 2023 | 1071 | 1.010 |
Why?
|
| Arteriolosclerosis | 6 | 2023 | 75 | 0.910 |
Why?
|
| Cerebrovascular Disorders | 8 | 2023 | 128 | 0.870 |
Why?
|
| White Matter | 7 | 2022 | 137 | 0.830 |
Why?
|
| Nervous System Diseases | 6 | 2023 | 118 | 0.820 |
Why?
|
| Disabled Persons | 8 | 2021 | 110 | 0.790 |
Why?
|
| Severity of Illness Index | 26 | 2019 | 830 | 0.770 |
Why?
|
| Middle Aged | 80 | 2021 | 8556 | 0.760 |
Why?
|
| Risk Factors | 37 | 2023 | 2173 | 0.750 |
Why?
|
| Hippocampus | 12 | 2022 | 267 | 0.700 |
Why?
|
| Amyloid beta-Peptides | 13 | 2024 | 318 | 0.700 |
Why?
|
| Movement | 15 | 2020 | 110 | 0.700 |
Why?
|
| Antiparkinson Agents | 12 | 2014 | 42 | 0.680 |
Why?
|
| Cerebral Infarction | 12 | 2020 | 147 | 0.670 |
Why?
|
| Diet, Mediterranean | 4 | 2023 | 101 | 0.650 |
Why?
|
| Autopsy | 19 | 2023 | 334 | 0.650 |
Why?
|
| Disease Progression | 28 | 2021 | 646 | 0.630 |
Why?
|
| Sleep Wake Disorders | 5 | 2016 | 115 | 0.620 |
Why?
|
| Motor Activity | 11 | 2018 | 309 | 0.620 |
Why?
|
| Residence Characteristics | 10 | 2021 | 206 | 0.610 |
Why?
|
| Models, Statistical | 3 | 2019 | 124 | 0.600 |
Why?
|
| Antipsychotic Agents | 3 | 2008 | 53 | 0.580 |
Why?
|
| DNA-Binding Proteins | 9 | 2022 | 260 | 0.580 |
Why?
|
| Disability Evaluation | 12 | 2019 | 257 | 0.580 |
Why?
|
| Memory | 13 | 2021 | 286 | 0.570 |
Why?
|
| Brain Infarction | 5 | 2021 | 75 | 0.550 |
Why?
|
| Movement Disorders | 7 | 2012 | 67 | 0.550 |
Why?
|
| Cerebral Amyloid Angiopathy | 6 | 2023 | 111 | 0.550 |
Why?
|
| Apolipoproteins E | 10 | 2023 | 248 | 0.530 |
Why?
|
| Prospective Studies | 23 | 2022 | 1686 | 0.530 |
Why?
|
| Geriatric Assessment | 9 | 2021 | 203 | 0.520 |
Why?
|
| Adult | 50 | 2022 | 7517 | 0.510 |
Why?
|
| Myoclonus | 5 | 2002 | 9 | 0.480 |
Why?
|
| Activities of Daily Living | 13 | 2020 | 584 | 0.480 |
Why?
|
| Motor Skills | 7 | 2021 | 48 | 0.480 |
Why?
|
| Spinal Cord | 4 | 2022 | 76 | 0.460 |
Why?
|
| Neurofibrillary Tangles | 10 | 2023 | 190 | 0.460 |
Why?
|
| Huntington Disease | 4 | 2010 | 45 | 0.450 |
Why?
|
| Mobility Limitation | 6 | 2020 | 91 | 0.440 |
Why?
|
| Stroke | 6 | 2019 | 262 | 0.430 |
Why?
|
| Psychomotor Performance | 11 | 2020 | 198 | 0.430 |
Why?
|
| Acculturation | 3 | 2023 | 31 | 0.420 |
Why?
|
| Memory, Short-Term | 9 | 2022 | 91 | 0.420 |
Why?
|
| Brain Mapping | 8 | 2017 | 147 | 0.420 |
Why?
|
| HIV Infections | 4 | 2021 | 475 | 0.410 |
Why?
|
| Memory, Episodic | 5 | 2022 | 116 | 0.410 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 1708 | 0.410 |
Why?
|
| Mortality | 3 | 2020 | 85 | 0.400 |
Why?
|
| Neurons | 7 | 2015 | 332 | 0.400 |
Why?
|
| Atherosclerosis | 2 | 2023 | 49 | 0.390 |
Why?
|
| Neuropathology | 5 | 2023 | 81 | 0.390 |
Why?
|
| Lewy Bodies | 12 | 2023 | 183 | 0.390 |
Why?
|
| Proportional Hazards Models | 13 | 2021 | 313 | 0.380 |
Why?
|
| Gait | 7 | 2020 | 409 | 0.380 |
Why?
|
| Cross-Sectional Studies | 16 | 2022 | 847 | 0.380 |
Why?
|
| Hypoxia | 3 | 2008 | 28 | 0.370 |
Why?
|
| Hypertension | 4 | 2022 | 176 | 0.360 |
Why?
|
| Flavonols | 2 | 2022 | 11 | 0.360 |
Why?
|
| Neurologic Examination | 10 | 2020 | 99 | 0.360 |
Why?
|
| Adolescent | 15 | 2019 | 2070 | 0.350 |
Why?
|
| tau Proteins | 7 | 2023 | 232 | 0.350 |
Why?
|
| Serotonin | 2 | 2002 | 23 | 0.350 |
Why?
|
| Refusal to Participate | 1 | 2010 | 2 | 0.350 |
Why?
|
| Neurodegenerative Diseases | 3 | 2018 | 124 | 0.340 |
Why?
|
| Exercise | 5 | 2021 | 415 | 0.340 |
Why?
|
| Dietary Approaches To Stop Hypertension | 2 | 2023 | 37 | 0.340 |
Why?
|
| Chicago | 13 | 2021 | 906 | 0.330 |
Why?
|
| Walking Speed | 2 | 2021 | 40 | 0.330 |
Why?
|
| F2-Isoprostanes | 1 | 2010 | 6 | 0.330 |
Why?
|
| Psychometrics | 4 | 2010 | 203 | 0.330 |
Why?
|
| Piperidines | 2 | 2006 | 12 | 0.330 |
Why?
|
| Temporal Lobe | 3 | 2018 | 87 | 0.330 |
Why?
|
| Brain Diseases | 2 | 2020 | 60 | 0.320 |
Why?
|
| Entorhinal Cortex | 4 | 2017 | 32 | 0.320 |
Why?
|
| Complementary Therapies | 1 | 2009 | 6 | 0.320 |
Why?
|
| Neuroimaging | 5 | 2022 | 125 | 0.320 |
Why?
|
| SNARE Proteins | 2 | 2021 | 13 | 0.320 |
Why?
|
| Exercise Therapy | 3 | 2015 | 82 | 0.310 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2022 | 22 | 0.310 |
Why?
|
| Plaque, Amyloid | 4 | 2015 | 143 | 0.310 |
Why?
|
| Wearable Electronic Devices | 2 | 2020 | 44 | 0.310 |
Why?
|
| Regression Analysis | 10 | 2021 | 246 | 0.310 |
Why?
|
| Literacy | 2 | 2021 | 17 | 0.310 |
Why?
|
| Lewy Body Disease | 5 | 2018 | 93 | 0.300 |
Why?
|
| Nerve Tissue Proteins | 3 | 2016 | 152 | 0.300 |
Why?
|
| Muscle Strength | 6 | 2019 | 129 | 0.300 |
Why?
|
| Dysautonomia, Familial | 1 | 2008 | 1 | 0.290 |
Why?
|
| Double-Blind Method | 13 | 2018 | 370 | 0.290 |
Why?
|
| Educational Status | 5 | 2021 | 283 | 0.290 |
Why?
|
| Incidence | 13 | 2020 | 720 | 0.290 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2008 | 25 | 0.290 |
Why?
|
| Quality of Life | 4 | 2013 | 563 | 0.280 |
Why?
|
| Motor Disorders | 2 | 2020 | 22 | 0.280 |
Why?
|
| Comorbidity | 11 | 2018 | 457 | 0.280 |
Why?
|
| Levodopa | 8 | 2009 | 34 | 0.280 |
Why?
|
| Supranuclear Palsy, Progressive | 5 | 2013 | 21 | 0.280 |
Why?
|
| Chorea | 2 | 2006 | 5 | 0.270 |
Why?
|
| Walking | 6 | 2022 | 250 | 0.270 |
Why?
|
| Neoplasms | 1 | 2009 | 220 | 0.270 |
Why?
|
| Memory Disorders | 6 | 2019 | 156 | 0.270 |
Why?
|
| Polymorphism, Genetic | 4 | 2011 | 53 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2006 | 155 | 0.260 |
Why?
|
| Cognitive Reserve | 2 | 2021 | 39 | 0.260 |
Why?
|
| Indans | 1 | 2006 | 5 | 0.260 |
Why?
|
| Myasthenia Gravis | 2 | 2004 | 33 | 0.260 |
Why?
|
| Anxiety Disorders | 3 | 2013 | 168 | 0.260 |
Why?
|
| Cognitive Aging | 2 | 2018 | 77 | 0.260 |
Why?
|
| Prefrontal Cortex | 3 | 2019 | 136 | 0.260 |
Why?
|
| Biomarkers | 6 | 2021 | 536 | 0.260 |
Why?
|
| Age Factors | 10 | 2020 | 738 | 0.260 |
Why?
|
| Seasons | 1 | 2006 | 18 | 0.250 |
Why?
|
| Algorithms | 6 | 2021 | 337 | 0.250 |
Why?
|
| Gray Matter | 3 | 2017 | 51 | 0.250 |
Why?
|
| Amyloid | 5 | 2021 | 56 | 0.250 |
Why?
|
| Diabetic Nephropathies | 2 | 1996 | 17 | 0.250 |
Why?
|
| Time | 2 | 2005 | 14 | 0.250 |
Why?
|
| Hypoxia, Brain | 3 | 2001 | 4 | 0.250 |
Why?
|
| Somatoform Disorders | 1 | 2005 | 15 | 0.250 |
Why?
|
| Apolipoprotein E4 | 6 | 2022 | 260 | 0.240 |
Why?
|
| Time Factors | 14 | 2020 | 1376 | 0.240 |
Why?
|
| Psychiatric Status Rating Scales | 11 | 2015 | 291 | 0.240 |
Why?
|
| United States | 13 | 2021 | 1935 | 0.230 |
Why?
|
| Loneliness | 3 | 2017 | 59 | 0.230 |
Why?
|
| Recovery of Function | 1 | 2006 | 296 | 0.230 |
Why?
|
| Animals | 12 | 2022 | 3504 | 0.230 |
Why?
|
| Self Report | 4 | 2022 | 207 | 0.230 |
Why?
|
| Accelerometry | 3 | 2020 | 89 | 0.230 |
Why?
|
| Surveys and Questionnaires | 9 | 2021 | 1083 | 0.230 |
Why?
|
| Gyrus Cinguli | 2 | 2014 | 14 | 0.220 |
Why?
|
| Prevalence | 7 | 2018 | 431 | 0.220 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2023 | 59 | 0.220 |
Why?
|
| Atrophy | 7 | 2014 | 82 | 0.220 |
Why?
|
| Depressive Disorder | 2 | 2019 | 168 | 0.220 |
Why?
|
| Hand Strength | 3 | 2021 | 56 | 0.220 |
Why?
|
| Gait Disorders, Neurologic | 5 | 2009 | 132 | 0.220 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2021 | 53 | 0.210 |
Why?
|
| Social Environment | 2 | 2021 | 76 | 0.210 |
Why?
|
| Mycophenolic Acid | 1 | 2003 | 8 | 0.210 |
Why?
|
| Death | 2 | 2021 | 43 | 0.210 |
Why?
|
| Antibodies, Antiphospholipid | 2 | 2014 | 23 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2011 | 359 | 0.210 |
Why?
|
| Statistics, Nonparametric | 6 | 2015 | 116 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2004 | 110 | 0.210 |
Why?
|
| DNA Methylation | 2 | 2015 | 161 | 0.210 |
Why?
|
| Video Recording | 2 | 2003 | 31 | 0.210 |
Why?
|
| Clinical Trials as Topic | 4 | 2004 | 196 | 0.210 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 277 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 2 | 2013 | 34 | 0.200 |
Why?
|
| Predictive Value of Tests | 10 | 2018 | 421 | 0.200 |
Why?
|
| Child | 8 | 2010 | 1180 | 0.200 |
Why?
|
| Cerebrum | 1 | 2023 | 9 | 0.200 |
Why?
|
| Lymphatic Vessels | 1 | 2022 | 9 | 0.200 |
Why?
|
| Linear Models | 7 | 2020 | 241 | 0.200 |
Why?
|
| Mental Recall | 2 | 2020 | 60 | 0.200 |
Why?
|
| Neural Pathways | 2 | 2014 | 63 | 0.200 |
Why?
|
| Cause of Death | 2 | 2021 | 56 | 0.190 |
Why?
|
| Frail Elderly | 3 | 2021 | 46 | 0.190 |
Why?
|
| Bone Marrow | 1 | 2022 | 71 | 0.190 |
Why?
|
| Glycation End Products, Advanced | 1 | 2022 | 7 | 0.190 |
Why?
|
| Health Resources | 1 | 2002 | 21 | 0.190 |
Why?
|
| Synapses | 2 | 2012 | 33 | 0.190 |
Why?
|
| Low Back Pain | 3 | 1999 | 129 | 0.190 |
Why?
|
| Quality Assurance, Health Care | 1 | 2002 | 30 | 0.190 |
Why?
|
| Crime Victims | 1 | 2022 | 31 | 0.190 |
Why?
|
| Mental Status Schedule | 6 | 2018 | 88 | 0.190 |
Why?
|
| Diet | 2 | 2022 | 214 | 0.190 |
Why?
|
| Placebo Effect | 3 | 2008 | 9 | 0.190 |
Why?
|
| Fragile X Syndrome | 2 | 2019 | 186 | 0.190 |
Why?
|
| Language Tests | 2 | 2019 | 22 | 0.190 |
Why?
|
| Hemoglobins | 2 | 2012 | 30 | 0.180 |
Why?
|
| Treatment Outcome | 13 | 2015 | 3339 | 0.180 |
Why?
|
| Perception | 2 | 2019 | 74 | 0.180 |
Why?
|
| Kidney | 2 | 2009 | 144 | 0.180 |
Why?
|
| Organ Size | 3 | 2019 | 93 | 0.180 |
Why?
|
| Brazil | 4 | 2021 | 42 | 0.180 |
Why?
|
| Interpersonal Relations | 3 | 2014 | 101 | 0.180 |
Why?
|
| Electromyography | 5 | 2008 | 71 | 0.180 |
Why?
|
| Hospitals | 1 | 2002 | 162 | 0.180 |
Why?
|
| Range of Motion, Articular | 3 | 2019 | 719 | 0.180 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2021 | 5 | 0.180 |
Why?
|
| Psychology | 1 | 2021 | 21 | 0.180 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2021 | 16 | 0.180 |
Why?
|
| Rats | 7 | 2021 | 628 | 0.180 |
Why?
|
| Memory and Learning Tests | 1 | 2020 | 7 | 0.170 |
Why?
|
| Serial Learning | 1 | 2020 | 7 | 0.170 |
Why?
|
| Vascular Diseases | 1 | 2021 | 41 | 0.170 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2021 | 45 | 0.170 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 61 | 0.170 |
Why?
|
| Frailty | 1 | 2021 | 30 | 0.170 |
Why?
|
| Sleep | 4 | 2016 | 323 | 0.170 |
Why?
|
| Music | 1 | 2021 | 22 | 0.170 |
Why?
|
| Motor Neurons | 3 | 2018 | 16 | 0.170 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2022 | 106 | 0.170 |
Why?
|
| Carrier Proteins | 1 | 2021 | 94 | 0.170 |
Why?
|
| Patient Selection | 1 | 2001 | 182 | 0.170 |
Why?
|
| Sarcopenia | 1 | 2021 | 31 | 0.170 |
Why?
|
| Videotape Recording | 5 | 2009 | 18 | 0.170 |
Why?
|
| Inflammation | 2 | 2022 | 277 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 143 | 0.170 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2000 | 2 | 0.160 |
Why?
|
| Data Interpretation, Statistical | 5 | 2016 | 75 | 0.160 |
Why?
|
| Physicians | 1 | 2001 | 113 | 0.160 |
Why?
|
| Financing, Personal | 1 | 2020 | 22 | 0.160 |
Why?
|
| Musculoskeletal Diseases | 2 | 2010 | 41 | 0.160 |
Why?
|
| Illinois | 5 | 2020 | 236 | 0.160 |
Why?
|
| Manipulation, Orthopedic | 1 | 1999 | 9 | 0.160 |
Why?
|
| Case-Control Studies | 8 | 2015 | 567 | 0.160 |
Why?
|
| Vocabulary | 1 | 2019 | 8 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2017 | 63 | 0.160 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 13 | 0.160 |
Why?
|
| Comprehension | 1 | 2019 | 30 | 0.160 |
Why?
|
| Postural Balance | 2 | 2018 | 113 | 0.160 |
Why?
|
| Sclerosis | 4 | 2022 | 68 | 0.160 |
Why?
|
| Language | 1 | 2019 | 53 | 0.160 |
Why?
|
| Emergency Service, Hospital | 1 | 2002 | 261 | 0.150 |
Why?
|
| Cerebral Arteries | 2 | 2016 | 23 | 0.150 |
Why?
|
| Dreams | 1 | 1999 | 2 | 0.150 |
Why?
|
| Cerebral Cortex | 4 | 2012 | 148 | 0.150 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2016 | 42 | 0.150 |
Why?
|
| Genetic Variation | 3 | 2011 | 91 | 0.150 |
Why?
|
| Prosthesis Failure | 1 | 2002 | 518 | 0.150 |
Why?
|
| Hypoventilation | 2 | 2010 | 38 | 0.150 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2018 | 5 | 0.150 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2019 | 25 | 0.150 |
Why?
|
| Postmortem Changes | 2 | 2016 | 31 | 0.150 |
Why?
|
| Knee Joint | 2 | 2019 | 758 | 0.150 |
Why?
|
| Genotype | 8 | 2015 | 335 | 0.150 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 619 | 0.150 |
Why?
|
| Amygdala | 1 | 2019 | 41 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 140 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2023 | 161 | 0.150 |
Why?
|
| Nerve Growth Factor | 2 | 2012 | 44 | 0.150 |
Why?
|
| Weight Gain | 2 | 1996 | 61 | 0.150 |
Why?
|
| Osteoarthritis, Hip | 1 | 2019 | 105 | 0.150 |
Why?
|
| Cholecystokinin | 2 | 2011 | 5 | 0.150 |
Why?
|
| Immunosenescence | 1 | 2018 | 4 | 0.150 |
Why?
|
| Muscle Contraction | 2 | 2008 | 63 | 0.150 |
Why?
|
| Fish Oils | 1 | 2018 | 5 | 0.150 |
Why?
|
| Tics | 3 | 2003 | 3 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 53 | 0.150 |
Why?
|
| Health Literacy | 1 | 2020 | 103 | 0.150 |
Why?
|
| Amnesia | 2 | 2009 | 21 | 0.150 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 1998 | 1 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 1998 | 9 | 0.140 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 21 | 0.140 |
Why?
|
| Diabetes Mellitus | 3 | 2017 | 120 | 0.140 |
Why?
|
| Decision Making | 1 | 2020 | 214 | 0.140 |
Why?
|
| Placebos | 3 | 2008 | 60 | 0.140 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2018 | 27 | 0.140 |
Why?
|
| Actigraphy | 3 | 2015 | 100 | 0.140 |
Why?
|
| Frontal Lobe | 1 | 2018 | 80 | 0.140 |
Why?
|
| Antihypertensive Agents | 2 | 2003 | 43 | 0.140 |
Why?
|
| Dyskinesias | 3 | 2009 | 10 | 0.140 |
Why?
|
| Osteoporosis | 1 | 2018 | 74 | 0.140 |
Why?
|
| Microvessels | 1 | 2017 | 13 | 0.140 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 18 | 0.140 |
Why?
|
| Learning | 1 | 2018 | 71 | 0.140 |
Why?
|
| Vision Disorders | 2 | 2012 | 18 | 0.140 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2017 | 4 | 0.140 |
Why?
|
| Odds Ratio | 5 | 2009 | 254 | 0.130 |
Why?
|
| Hip Prosthesis | 1 | 2002 | 535 | 0.130 |
Why?
|
| Pain | 2 | 2010 | 401 | 0.130 |
Why?
|
| Young Adult | 6 | 2019 | 1929 | 0.130 |
Why?
|
| Logistic Models | 7 | 2016 | 368 | 0.130 |
Why?
|
| Muscle Rigidity | 3 | 2014 | 20 | 0.130 |
Why?
|
| Risk | 5 | 2016 | 202 | 0.130 |
Why?
|
| Cytokines | 1 | 2018 | 231 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 264 | 0.130 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 29 | 0.130 |
Why?
|
| Blood Pressure | 4 | 2022 | 179 | 0.130 |
Why?
|
| Biostatistics | 1 | 2016 | 5 | 0.130 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1996 | 5 | 0.130 |
Why?
|
| Pregnancy, Multiple | 1 | 1996 | 4 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 1996 | 20 | 0.120 |
Why?
|
| Peptide Fragments | 2 | 2014 | 72 | 0.120 |
Why?
|
| Munc18 Proteins | 1 | 2015 | 3 | 0.120 |
Why?
|
| GABAergic Neurons | 1 | 2015 | 4 | 0.120 |
Why?
|
| Substantia Nigra | 2 | 2019 | 115 | 0.120 |
Why?
|
| Survival Analysis | 6 | 2009 | 234 | 0.120 |
Why?
|
| Dyskinesia, Drug-Induced | 2 | 2008 | 9 | 0.120 |
Why?
|
| Health Status | 2 | 2009 | 198 | 0.120 |
Why?
|
| Cumulative Trauma Disorders | 2 | 1995 | 17 | 0.120 |
Why?
|
| Alleles | 6 | 2015 | 200 | 0.120 |
Why?
|
| Single-Blind Method | 6 | 2015 | 100 | 0.120 |
Why?
|
| Analysis of Variance | 7 | 2013 | 248 | 0.120 |
Why?
|
| Lung | 2 | 2021 | 165 | 0.120 |
Why?
|
| Misoprostol | 1 | 1995 | 4 | 0.120 |
Why?
|
| Ibuprofen | 1 | 1995 | 11 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2004 | 36 | 0.120 |
Why?
|
| Spectrophotometry | 1 | 1995 | 5 | 0.120 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1995 | 9 | 0.120 |
Why?
|
| Genome, Human | 1 | 2015 | 44 | 0.120 |
Why?
|
| Antiporters | 1 | 2015 | 5 | 0.120 |
Why?
|
| HLA-DRB5 Chains | 1 | 2015 | 5 | 0.120 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 16 | 0.120 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2015 | 15 | 0.120 |
Why?
|
| Computer Simulation | 3 | 2016 | 176 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 34 | 0.110 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2014 | 16 | 0.110 |
Why?
|
| Biomechanical Phenomena | 7 | 2019 | 639 | 0.110 |
Why?
|
| Radius | 1 | 2014 | 33 | 0.110 |
Why?
|
| Genome-Wide Association Study | 2 | 2015 | 268 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 65 | 0.110 |
Why?
|
| Wrist | 1 | 1994 | 16 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2002 | 804 | 0.110 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2014 | 4 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 85 | 0.110 |
Why?
|
| Arthrodesis | 1 | 2014 | 39 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2015 | 53 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1996 | 155 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 1995 | 80 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 86 | 0.110 |
Why?
|
| Catholicism | 2 | 2013 | 19 | 0.110 |
Why?
|
| Pilot Projects | 4 | 2004 | 394 | 0.110 |
Why?
|
| Dopamine Agonists | 3 | 2004 | 15 | 0.110 |
Why?
|
| Financial Management | 1 | 2014 | 23 | 0.110 |
Why?
|
| Sex Characteristics | 3 | 2022 | 115 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 1995 | 110 | 0.110 |
Why?
|
| Hip Joint | 2 | 2019 | 555 | 0.110 |
Why?
|
| Locomotion | 1 | 2014 | 24 | 0.110 |
Why?
|
| Muscle Weakness | 3 | 2008 | 33 | 0.110 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 450 | 0.110 |
Why?
|
| Sex Factors | 5 | 2020 | 453 | 0.110 |
Why?
|
| Cholinergic Antagonists | 1 | 2013 | 8 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 258 | 0.100 |
Why?
|
| Essential Tremor | 1 | 2013 | 5 | 0.100 |
Why?
|
| Dyssomnias | 1 | 2013 | 6 | 0.100 |
Why?
|
| Basal Ganglia | 1 | 2013 | 14 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 125 | 0.100 |
Why?
|
| Cerebellum | 1 | 2013 | 39 | 0.100 |
Why?
|
| Genetic Association Studies | 4 | 2015 | 82 | 0.100 |
Why?
|
| Estrogens | 3 | 2001 | 25 | 0.100 |
Why?
|
| Multiple System Atrophy | 1 | 2013 | 30 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 15 | 0.100 |
Why?
|
| Infarction | 2 | 2023 | 28 | 0.100 |
Why?
|
| Protein Precursors | 1 | 2012 | 20 | 0.100 |
Why?
|
| Locus Coeruleus | 1 | 2012 | 17 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 3 | 1998 | 29 | 0.100 |
Why?
|
| Torticollis | 2 | 2005 | 8 | 0.100 |
Why?
|
| Neck Muscles | 2 | 2005 | 6 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 37 | 0.100 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Qa-SNARE Proteins | 1 | 2012 | 7 | 0.100 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2020 | 53 | 0.100 |
Why?
|
| Models, Psychological | 1 | 2012 | 66 | 0.090 |
Why?
|
| Eating | 2 | 2022 | 57 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 1998 | 169 | 0.090 |
Why?
|
| Automobile Driving | 1 | 2012 | 20 | 0.090 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2011 | 5 | 0.090 |
Why?
|
| Neuroticism | 3 | 2021 | 32 | 0.090 |
Why?
|
| Prognosis | 6 | 2019 | 695 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 328 | 0.090 |
Why?
|
| Causality | 2 | 2009 | 53 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2009 | 590 | 0.090 |
Why?
|
| Twins | 3 | 1996 | 9 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 196 | 0.090 |
Why?
|
| Abnormalities, Multiple | 2 | 2010 | 13 | 0.090 |
Why?
|
| Carbidopa | 2 | 2009 | 4 | 0.090 |
Why?
|
| Thiazoles | 2 | 2002 | 17 | 0.090 |
Why?
|
| Quercetin | 2 | 2022 | 11 | 0.090 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2010 | 24 | 0.090 |
Why?
|
| Dopamine | 2 | 2004 | 82 | 0.090 |
Why?
|
| Kaempferols | 2 | 2022 | 12 | 0.090 |
Why?
|
| Anisotropy | 3 | 2023 | 43 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2021 | 319 | 0.090 |
Why?
|
| Tibial Meniscus Injuries | 1 | 2012 | 86 | 0.090 |
Why?
|
| Homeodomain Proteins | 2 | 2010 | 59 | 0.090 |
Why?
|
| Space Perception | 2 | 2019 | 22 | 0.090 |
Why?
|
| Polysomnography | 2 | 2008 | 79 | 0.090 |
Why?
|
| Receptors, Complement 3b | 1 | 2011 | 14 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2012 | 161 | 0.090 |
Why?
|
| Body Mass Index | 4 | 2016 | 431 | 0.090 |
Why?
|
| Wakefulness | 1 | 2011 | 88 | 0.090 |
Why?
|
| Dystonia | 2 | 2003 | 12 | 0.090 |
Why?
|
| Contrast Sensitivity | 2 | 2002 | 6 | 0.090 |
Why?
|
| Reference Values | 6 | 2012 | 175 | 0.090 |
Why?
|
| Self-Assessment | 2 | 2021 | 27 | 0.090 |
Why?
|
| Physical Therapy Modalities | 2 | 2022 | 73 | 0.090 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 15 | 0.090 |
Why?
|
| Dystonic Disorders | 2 | 2008 | 2 | 0.090 |
Why?
|
| Statistics as Topic | 4 | 2017 | 103 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2010 | 163 | 0.090 |
Why?
|
| Research Design | 3 | 2021 | 176 | 0.080 |
Why?
|
| Family Health | 1 | 2010 | 31 | 0.080 |
Why?
|
| Telephone | 1 | 2010 | 26 | 0.080 |
Why?
|
| CA3 Region, Hippocampal | 1 | 2010 | 5 | 0.080 |
Why?
|
| Observer Variation | 3 | 2005 | 95 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 18 | 0.080 |
Why?
|
| Menisci, Tibial | 1 | 2012 | 173 | 0.080 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2008 | 22 | 0.080 |
Why?
|
| Nerve Degeneration | 1 | 2010 | 47 | 0.080 |
Why?
|
| Religion and Psychology | 1 | 2010 | 24 | 0.080 |
Why?
|
| Depression | 4 | 2014 | 410 | 0.080 |
Why?
|
| Substantia Innominata | 1 | 2009 | 5 | 0.080 |
Why?
|
| Drug Design | 1 | 2009 | 22 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2018 | 553 | 0.080 |
Why?
|
| Muscle, Skeletal | 3 | 2009 | 378 | 0.080 |
Why?
|
| Knee Injuries | 1 | 2012 | 202 | 0.080 |
Why?
|
| Serotonin Antagonists | 2 | 2000 | 8 | 0.080 |
Why?
|
| Prejudice | 1 | 2009 | 35 | 0.080 |
Why?
|
| Genes, p53 | 3 | 1998 | 19 | 0.080 |
Why?
|
| Somatosensory Disorders | 1 | 2009 | 11 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 95 | 0.080 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 23 | 0.080 |
Why?
|
| Proteomics | 2 | 2021 | 88 | 0.080 |
Why?
|
| Social Adjustment | 1 | 2009 | 23 | 0.080 |
Why?
|
| Adoption | 2 | 1979 | 2 | 0.080 |
Why?
|
| Fertility | 2 | 1979 | 13 | 0.080 |
Why?
|
| Vibration | 1 | 2009 | 27 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2009 | 35 | 0.080 |
Why?
|
| Brain Chemistry | 2 | 2007 | 42 | 0.080 |
Why?
|
| Likelihood Functions | 3 | 2016 | 25 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2006 | 314 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2008 | 11 | 0.070 |
Why?
|
| Respiratory Muscles | 1 | 2008 | 18 | 0.070 |
Why?
|
| Accidental Falls | 1 | 2010 | 109 | 0.070 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2008 | 2 | 0.070 |
Why?
|
| Mathematics | 2 | 2021 | 29 | 0.070 |
Why?
|
| Tauopathies | 1 | 2008 | 20 | 0.070 |
Why?
|
| Interviews as Topic | 2 | 2021 | 129 | 0.070 |
Why?
|
| Swine | 1 | 2008 | 66 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 158 | 0.070 |
Why?
|
| Monitoring, Ambulatory | 1 | 2008 | 18 | 0.070 |
Why?
|
| Death, Sudden | 1 | 2008 | 7 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 280 | 0.070 |
Why?
|
| Acoustic Stimulation | 3 | 2004 | 48 | 0.070 |
Why?
|
| Models, Biological | 2 | 2008 | 285 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2013 | 149 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2012 | 104 | 0.070 |
Why?
|
| Birth Weight | 3 | 1996 | 37 | 0.070 |
Why?
|
| Receptors, Cholinergic | 2 | 2004 | 24 | 0.070 |
Why?
|
| Deglutition Disorders | 2 | 2005 | 31 | 0.070 |
Why?
|
| Dioxoles | 1 | 2006 | 5 | 0.070 |
Why?
|
| Receptors, AMPA | 1 | 2006 | 7 | 0.070 |
Why?
|
| Estradiol | 2 | 2004 | 46 | 0.070 |
Why?
|
| Child Behavior Disorders | 1 | 2006 | 20 | 0.060 |
Why?
|
| Pregnancy | 6 | 1996 | 327 | 0.060 |
Why?
|
| Nootropic Agents | 1 | 2006 | 14 | 0.060 |
Why?
|
| Nerve Fibers | 1 | 2006 | 12 | 0.060 |
Why?
|
| Darkness | 1 | 2006 | 8 | 0.060 |
Why?
|
| Wrist Joint | 3 | 2014 | 59 | 0.060 |
Why?
|
| Motor Cortex | 1 | 2006 | 17 | 0.060 |
Why?
|
| Weights and Measures | 1 | 2005 | 3 | 0.060 |
Why?
|
| Psychophysiologic Disorders | 1 | 2005 | 7 | 0.060 |
Why?
|
| Interview, Psychological | 1 | 2006 | 41 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 1998 | 143 | 0.060 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2005 | 8 | 0.060 |
Why?
|
| Botulinum Toxins | 1 | 2005 | 8 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 235 | 0.060 |
Why?
|
| Light | 1 | 2006 | 56 | 0.060 |
Why?
|
| Awareness | 1 | 2006 | 41 | 0.060 |
Why?
|
| Cholesterol | 2 | 2022 | 62 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 220 | 0.060 |
Why?
|
| Infant | 2 | 2023 | 503 | 0.060 |
Why?
|
| Psychotherapy | 1 | 2005 | 37 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 70 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 355 | 0.060 |
Why?
|
| Sex Distribution | 3 | 2012 | 73 | 0.060 |
Why?
|
| West Nile Fever | 1 | 2005 | 2 | 0.060 |
Why?
|
| Community Health Planning | 2 | 2018 | 19 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 118 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 27 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2021 | 3342 | 0.060 |
Why?
|
| CpG Islands | 2 | 2015 | 54 | 0.060 |
Why?
|
| Progesterone | 2 | 2001 | 19 | 0.060 |
Why?
|
| Nursing Homes | 1 | 2005 | 42 | 0.060 |
Why?
|
| Apoptosis | 2 | 2012 | 204 | 0.060 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2004 | 2 | 0.060 |
Why?
|
| Acute Disease | 2 | 2002 | 165 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2003 | 589 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 77 | 0.060 |
Why?
|
| Reaction Time | 2 | 2021 | 99 | 0.060 |
Why?
|
| Speech | 2 | 2005 | 23 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2011 | 55 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 3 | 2010 | 50 | 0.060 |
Why?
|
| Cholinergic Fibers | 1 | 2004 | 9 | 0.060 |
Why?
|
| Prosencephalon | 1 | 2004 | 8 | 0.060 |
Why?
|
| Menstrual Cycle | 2 | 2001 | 17 | 0.060 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2004 | 5 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 20 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2004 | 11 | 0.050 |
Why?
|
| Fibromyalgia | 1 | 2004 | 21 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2004 | 24 | 0.050 |
Why?
|
| Syndrome | 3 | 2010 | 69 | 0.050 |
Why?
|
| Occupational Diseases | 2 | 1995 | 23 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2014 | 193 | 0.050 |
Why?
|
| Heterozygote | 2 | 2015 | 98 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 7 | 0.050 |
Why?
|
| Walkers | 1 | 2003 | 1 | 0.050 |
Why?
|
| Spinal Stenosis | 1 | 2004 | 35 | 0.050 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 43 | 0.050 |
Why?
|
| Migraine Disorders | 1 | 2004 | 19 | 0.050 |
Why?
|
| Diabetes Complications | 2 | 2020 | 56 | 0.050 |
Why?
|
| Ticlopidine | 1 | 2003 | 5 | 0.050 |
Why?
|
| Spinal Cord Diseases | 1 | 2004 | 47 | 0.050 |
Why?
|
| Antibodies | 1 | 2003 | 44 | 0.050 |
Why?
|
| Speech Disorders | 1 | 2003 | 10 | 0.050 |
Why?
|
| Dependovirus | 1 | 2003 | 39 | 0.050 |
Why?
|
| Receptors, Serotonin | 2 | 2000 | 12 | 0.050 |
Why?
|
| Lymphatic System | 1 | 2022 | 4 | 0.050 |
Why?
|
| Arachnoid | 1 | 2022 | 6 | 0.050 |
Why?
|
| Olfactory Bulb | 1 | 2023 | 15 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 19 | 0.050 |
Why?
|
| Nerve Growth Factors | 1 | 2003 | 38 | 0.050 |
Why?
|
| Age of Onset | 1 | 2003 | 95 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2003 | 49 | 0.050 |
Why?
|
| Microcirculation | 3 | 2011 | 28 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2003 | 27 | 0.050 |
Why?
|
| Sphenoid Bone | 1 | 2002 | 5 | 0.050 |
Why?
|
| Copper | 1 | 2022 | 18 | 0.050 |
Why?
|
| Triglycerides | 1 | 2022 | 56 | 0.050 |
Why?
|
| Cell Count | 3 | 2012 | 76 | 0.050 |
Why?
|
| Dura Mater | 1 | 2022 | 19 | 0.050 |
Why?
|
| Color Vision Defects | 1 | 2002 | 3 | 0.050 |
Why?
|
| Aspirin | 1 | 2003 | 58 | 0.050 |
Why?
|
| Electrodes, Implanted | 1 | 2002 | 22 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 35 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2003 | 86 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2009 | 36 | 0.050 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2002 | 30 | 0.050 |
Why?
|
| Fraud | 1 | 2022 | 21 | 0.050 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2002 | 8 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2022 | 9 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2023 | 98 | 0.050 |
Why?
|
| Acetylcholine | 1 | 2002 | 7 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2002 | 83 | 0.050 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2002 | 10 | 0.050 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2002 | 10 | 0.050 |
Why?
|
| Device Removal | 1 | 2002 | 80 | 0.050 |
Why?
|
| Corrosion | 1 | 2002 | 125 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2002 | 62 | 0.050 |
Why?
|
| Guinea Pigs | 1 | 2002 | 23 | 0.050 |
Why?
|
| Equipment Failure Analysis | 1 | 2002 | 96 | 0.050 |
Why?
|
| Alloys | 1 | 2002 | 92 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 11 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2002 | 43 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 27 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2003 | 403 | 0.050 |
Why?
|
| Executive Function | 1 | 2022 | 110 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 89 | 0.050 |
Why?
|
| Cell Division | 2 | 1998 | 80 | 0.040 |
Why?
|
| Cadaver | 2 | 2013 | 375 | 0.040 |
Why?
|
| Probability | 1 | 2021 | 84 | 0.040 |
Why?
|
| Spatial Processing | 1 | 2021 | 6 | 0.040 |
Why?
|
| Acute-Phase Proteins | 1 | 2021 | 10 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 22 | 0.040 |
Why?
|
| Lumbar Vertebrae | 2 | 2018 | 385 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2021 | 11 | 0.040 |
Why?
|
| Receptors, Dopamine | 1 | 2001 | 8 | 0.040 |
Why?
|
| Isometric Contraction | 1 | 2000 | 13 | 0.040 |
Why?
|
| Writing | 1 | 2021 | 17 | 0.040 |
Why?
|
| Pergolide | 1 | 2000 | 2 | 0.040 |
Why?
|
| Reading | 1 | 2021 | 37 | 0.040 |
Why?
|
| Pirenzepine | 1 | 2000 | 5 | 0.040 |
Why?
|
| Hypotension, Orthostatic | 1 | 2000 | 10 | 0.040 |
Why?
|
| Clozapine | 1 | 2000 | 5 | 0.040 |
Why?
|
| Retirement | 2 | 2011 | 12 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2003 | 99 | 0.040 |
Why?
|
| Indoles | 1 | 2000 | 31 | 0.040 |
Why?
|
| Sensory Aids | 1 | 2000 | 1 | 0.040 |
Why?
|
| Apomorphine | 1 | 2000 | 3 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2002 | 477 | 0.040 |
Why?
|
| Flavonoids | 1 | 2020 | 19 | 0.040 |
Why?
|
| Protective Factors | 1 | 2020 | 23 | 0.040 |
Why?
|
| Amyloid Neuropathies | 1 | 2020 | 4 | 0.040 |
Why?
|
| Cues | 1 | 2000 | 38 | 0.040 |
Why?
|
| Family | 1 | 2021 | 95 | 0.040 |
Why?
|
| Manipulation, Spinal | 1 | 1999 | 3 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 47 | 0.040 |
Why?
|
| Fitness Trackers | 1 | 2019 | 13 | 0.040 |
Why?
|
| Rotation | 1 | 2019 | 138 | 0.040 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2019 | 17 | 0.040 |
Why?
|
| Delusions | 1 | 1999 | 9 | 0.040 |
Why?
|
| Analgesics | 1 | 1999 | 80 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 106 | 0.040 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1998 | 4 | 0.040 |
Why?
|
| Color Perception | 1 | 1998 | 5 | 0.040 |
Why?
|
| Head Movements | 1 | 1998 | 6 | 0.040 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 23 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2018 | 50 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2018 | 61 | 0.040 |
Why?
|
| Sample Size | 1 | 1998 | 17 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 1998 | 24 | 0.040 |
Why?
|
| Laryngeal Neoplasms | 1 | 1998 | 34 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 125 | 0.030 |
Why?
|
| Dementia, Vascular | 1 | 2018 | 44 | 0.030 |
Why?
|
| Microglia | 1 | 2018 | 136 | 0.030 |
Why?
|
| Amyloidosis | 1 | 2017 | 21 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 58 | 0.030 |
Why?
|
| Vesicular Inhibitory Amino Acid Transport Proteins | 1 | 2016 | 3 | 0.030 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Rats, Long-Evans | 1 | 2016 | 11 | 0.030 |
Why?
|
| Presynaptic Terminals | 1 | 2016 | 11 | 0.030 |
Why?
|
| Maze Learning | 1 | 2016 | 16 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2017 | 148 | 0.030 |
Why?
|
| Creatinine | 1 | 1996 | 37 | 0.030 |
Why?
|
| Consciousness Disorders | 1 | 2016 | 6 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 1999 | 314 | 0.030 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 1996 | 2 | 0.030 |
Why?
|
| Obstetric Labor, Premature | 1 | 1996 | 3 | 0.030 |
Why?
|
| PubMed | 1 | 2016 | 7 | 0.030 |
Why?
|
| Religious Personnel | 1 | 2016 | 11 | 0.030 |
Why?
|
| Proteinuria | 1 | 1996 | 48 | 0.030 |
Why?
|
| Arterioles | 1 | 2016 | 9 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1996 | 39 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 1996 | 37 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 43 | 0.030 |
Why?
|
| Mutation | 3 | 2008 | 319 | 0.030 |
Why?
|
| Intensive Care, Neonatal | 1 | 1996 | 30 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1996 | 58 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1995 | 6 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Tuberous Sclerosis | 1 | 2015 | 13 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1995 | 53 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 1996 | 102 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 31 | 0.030 |
Why?
|
| Renal Circulation | 1 | 1995 | 4 | 0.030 |
Why?
|
| Triplets | 1 | 1995 | 1 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 40 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1995 | 57 | 0.030 |
Why?
|
| Graft Rejection | 1 | 1995 | 63 | 0.030 |
Why?
|
| Supination | 1 | 2014 | 17 | 0.030 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2014 | 7 | 0.030 |
Why?
|
| Phosphatidylserines | 1 | 2014 | 7 | 0.030 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2014 | 7 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 1996 | 111 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 38 | 0.030 |
Why?
|
| Neuronal Plasticity | 2 | 2006 | 48 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1995 | 99 | 0.030 |
Why?
|
| Smoking | 1 | 1996 | 173 | 0.030 |
Why?
|
| Industry | 1 | 1994 | 5 | 0.030 |
Why?
|
| Software | 1 | 1995 | 60 | 0.030 |
Why?
|
| Autoantigens | 1 | 2014 | 25 | 0.030 |
Why?
|
| Kinetics | 1 | 1995 | 151 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 139 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 38 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 25 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2009 | 55 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 1995 | 86 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 28 | 0.030 |
Why?
|
| Sepsis | 1 | 1995 | 111 | 0.030 |
Why?
|
| Hypokinesia | 1 | 2014 | 22 | 0.030 |
Why?
|
| Choline O-Acetyltransferase | 2 | 2004 | 21 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 141 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 35 | 0.030 |
Why?
|
| Leg | 2 | 2008 | 48 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 211 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2013 | 50 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2013 | 54 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2013 | 41 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 54 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 131 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2013 | 45 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 153 | 0.020 |
Why?
|
| Tremor | 1 | 2014 | 103 | 0.020 |
Why?
|
| Ovariectomy | 2 | 2004 | 26 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2014 | 224 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 87 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 1390 | 0.020 |
Why?
|
| Bone Transplantation | 1 | 2014 | 203 | 0.020 |
Why?
|
| R-SNARE Proteins | 1 | 2012 | 2 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 4 | 0.020 |
Why?
|
| Clergy | 1 | 2013 | 88 | 0.020 |
Why?
|
| Spatial Behavior | 1 | 2012 | 8 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 13 | 0.020 |
Why?
|
| Licensure | 1 | 2012 | 8 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 11 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 25 | 0.020 |
Why?
|
| Rest | 1 | 2012 | 32 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 21 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2012 | 43 | 0.020 |
Why?
|
| Environment | 1 | 2012 | 39 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 7 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 167 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 41 | 0.020 |
Why?
|
| Benzothiazoles | 2 | 2002 | 3 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2011 | 3 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 31 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 62 | 0.020 |
Why?
|
| Visual Perception | 1 | 2011 | 29 | 0.020 |
Why?
|
| Endophenotypes | 1 | 2011 | 11 | 0.020 |
Why?
|
| Vision Tests | 2 | 2002 | 4 | 0.020 |
Why?
|
| Reoperation | 1 | 2014 | 912 | 0.020 |
Why?
|
| Dendritic Spines | 1 | 2010 | 9 | 0.020 |
Why?
|
| Dendrites | 1 | 2010 | 9 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2010 | 16 | 0.020 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2009 | 17 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 28 | 0.020 |
Why?
|
| Tablets | 1 | 2009 | 3 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2009 | 31 | 0.020 |
Why?
|
| Mechanoreceptors | 1 | 2009 | 7 | 0.020 |
Why?
|
| Neocortex | 1 | 2009 | 30 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 1989 | 2 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2009 | 11 | 0.020 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2009 | 17 | 0.020 |
Why?
|
| Proprioception | 1 | 2009 | 20 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 63 | 0.020 |
Why?
|
| Phenytoin | 1 | 1989 | 6 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 83 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2009 | 33 | 0.020 |
Why?
|
| Child Development | 1 | 2010 | 69 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2009 | 54 | 0.020 |
Why?
|
| Heart Arrest | 2 | 2001 | 38 | 0.020 |
Why?
|
| Joints | 1 | 2009 | 68 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 284 | 0.020 |
Why?
|
| Mass Screening | 1 | 2010 | 168 | 0.020 |
Why?
|
| Arm | 1 | 2008 | 83 | 0.020 |
Why?
|
| Physical Fitness | 1 | 2008 | 42 | 0.020 |
Why?
|
| Hand | 1 | 2008 | 40 | 0.020 |
Why?
|
| Fatigue | 1 | 2008 | 56 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2008 | 10 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2008 | 118 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 301 | 0.020 |
Why?
|
| Action Potentials | 1 | 2008 | 82 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 200 | 0.020 |
Why?
|
| Self Care | 1 | 2008 | 83 | 0.020 |
Why?
|
| Urban Population | 1 | 2008 | 146 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 61 | 0.020 |
Why?
|
| Isoprostanes | 1 | 2007 | 2 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 9 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 36 | 0.020 |
Why?
|
| Elbow Joint | 1 | 2008 | 126 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2006 | 7 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2006 | 13 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 23 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2006 | 33 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2006 | 22 | 0.020 |
Why?
|
| von Willebrand Factor | 2 | 1996 | 9 | 0.020 |
Why?
|
| Somatosensory Cortex | 1 | 2006 | 1 | 0.020 |
Why?
|
| Autistic Disorder | 1 | 2006 | 39 | 0.020 |
Why?
|
| Xerostomia | 1 | 2005 | 6 | 0.020 |
Why?
|
| Spain | 1 | 2005 | 7 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2005 | 37 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 30 | 0.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2005 | 11 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 92 | 0.010 |
Why?
|
| Gestational Age | 2 | 1996 | 74 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 22 | 0.010 |
Why?
|
| Etanercept | 1 | 2004 | 21 | 0.010 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2005 | 87 | 0.010 |
Why?
|
| Anxiety | 1 | 2005 | 143 | 0.010 |
Why?
|
| Prednisone | 1 | 2004 | 63 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 2004 | 11 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2004 | 62 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2004 | 74 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2004 | 60 | 0.010 |
Why?
|
| Selection Bias | 1 | 2004 | 9 | 0.010 |
Why?
|
| Contrast Media | 1 | 2004 | 58 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 190 | 0.010 |
Why?
|
| Immobilization | 1 | 2003 | 13 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1996 | 553 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 2003 | 6 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2003 | 11 | 0.010 |
Why?
|
| Nitro Compounds | 1 | 2003 | 9 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 20 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 7 | 0.010 |
Why?
|
| Propionates | 1 | 2003 | 11 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 2003 | 15 | 0.010 |
Why?
|
| Injections | 1 | 2003 | 42 | 0.010 |
Why?
|
| Life Tables | 1 | 2003 | 5 | 0.010 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2003 | 26 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2003 | 50 | 0.010 |
Why?
|
| Corpus Striatum | 1 | 2003 | 65 | 0.010 |
Why?
|
| Heart Septum | 1 | 2002 | 1 | 0.010 |
Why?
|
| Casein Kinases | 1 | 2002 | 2 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2003 | 23 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2002 | 12 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2002 | 23 | 0.010 |
Why?
|
| Hypolipidemic Agents | 1 | 2003 | 26 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2002 | 57 | 0.010 |
Why?
|
| Epitopes | 1 | 2002 | 40 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 77 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2002 | 42 | 0.010 |
Why?
|
| Biological Availability | 1 | 2002 | 13 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 290 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 34 | 0.010 |
Why?
|
| Selegiline | 1 | 2002 | 2 | 0.010 |
Why?
|
| Tocopherols | 1 | 2002 | 8 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2002 | 61 | 0.010 |
Why?
|
| Shoulder Joint | 1 | 2008 | 656 | 0.010 |
Why?
|
| Postmenopause | 1 | 2002 | 51 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 113 | 0.010 |
Why?
|
| Globus Pallidus | 1 | 2001 | 10 | 0.010 |
Why?
|
| Brain Tissue Transplantation | 1 | 2001 | 15 | 0.010 |
Why?
|
| Physicians' Offices | 1 | 2001 | 3 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2003 | 328 | 0.010 |
Why?
|
| Drug Implants | 1 | 2001 | 8 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2001 | 63 | 0.010 |
Why?
|
| Behavior | 1 | 2000 | 25 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 631 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 2000 | 46 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 2004 | 287 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2001 | 50 | 0.010 |
Why?
|
| Elbow | 1 | 2000 | 49 | 0.010 |
Why?
|
| Larynx | 1 | 2000 | 10 | 0.010 |
Why?
|
| Ergolines | 1 | 1999 | 1 | 0.010 |
Why?
|
| Methiothepin | 1 | 1999 | 1 | 0.010 |
Why?
|
| Infertility, Male | 1 | 1979 | 5 | 0.010 |
Why?
|
| Oxadiazoles | 1 | 1999 | 8 | 0.010 |
Why?
|
| Infertility, Female | 1 | 1979 | 22 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 1998 | 1 | 0.010 |
Why?
|
| Genes, bcl-1 | 1 | 1998 | 2 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 1998 | 4 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1998 | 17 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1998 | 29 | 0.010 |
Why?
|
| Piperazines | 1 | 1999 | 77 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1998 | 30 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1998 | 116 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 4 | 0.010 |
Why?
|
| S Phase | 1 | 1997 | 11 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 77 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 25 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1998 | 286 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 117 | 0.010 |
Why?
|
| Hemiplegia | 1 | 1996 | 4 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1998 | 160 | 0.010 |
Why?
|
| Gene Expression | 1 | 1997 | 197 | 0.010 |
Why?
|
| Morbidity | 1 | 1996 | 50 | 0.010 |
Why?
|
| Health Services Research | 1 | 1996 | 38 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1995 | 27 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 33 | 0.010 |
Why?
|
| Survival Rate | 1 | 1996 | 294 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1995 | 96 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1995 | 89 | 0.010 |
Why?
|
| Lifting | 1 | 1995 | 3 | 0.010 |
Why?
|
| Twins, Dizygotic | 1 | 1995 | 3 | 0.010 |
Why?
|
| Fetal Growth Retardation | 1 | 1995 | 3 | 0.010 |
Why?
|
| Growth | 1 | 1995 | 6 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 1996 | 186 | 0.010 |
Why?
|
| Twins, Monozygotic | 1 | 1995 | 8 | 0.010 |
Why?
|
| Graft Survival | 1 | 1995 | 89 | 0.010 |
Why?
|
| Uterus | 1 | 1995 | 17 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 177 | 0.010 |
Why?
|
| Body Height | 1 | 1995 | 35 | 0.010 |
Why?
|
| Posture | 1 | 1995 | 60 | 0.010 |
Why?
|
| Body Weight | 1 | 1995 | 130 | 0.010 |
Why?
|
| Length of Stay | 1 | 1996 | 307 | 0.010 |
Why?
|
| Spine | 1 | 1995 | 103 | 0.010 |
Why?
|
| Weight-Bearing | 1 | 1993 | 157 | 0.010 |
Why?
|
| Enzymes | 1 | 1989 | 4 | 0.000 |
Why?
|
| Protein Binding | 1 | 1989 | 114 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1995 | 893 | 0.000 |
Why?
|
| Epilepsy | 1 | 1989 | 69 | 0.000 |
Why?
|